

Acquisition Brief — neuromax.ai



Domain name / Asset offered: neuromax.ai (*single asset; no other extensions included*)

Purpose: acquisition of a strategic banner to run a **Neuro/AI excellence program** (R&D, data, safety/ethics, clinical/industry partnerships).

Contacts

Email • contact@neuromax.ai

Website • <https://www.neuromax.ai>

LinkedIn • <https://www.linkedin.com/company/neuromaxai>

This document — who it's for, why

Decision-grade brief for **CEO / COO / CFO / CTO / Regulatory & Compliance** (digital health, medtech/BCI, neuro-AI, pharma, devices, deeptech).

Thesis: **owning the category language** creates operational and reputational edge.

NEUROMAX.AI is a neutral, memorable banner to align **R&D, Data, Clinical, Quality/Regulatory, Security & Ethics**.

1) One-page decision

What it is. A **strategic asset** (.ai) to **structure & signal** a Neuro/AI program: public portal, references, resources, ecosystem voice.

What it changes. A **single entry point** → clear governance, stronger partner/talent pull, shorter evaluation cycles, improved **time-to-trust**.

What you can deploy today.

- **“Neuro/AI — Readiness & Rollout”.** Use-case roadmap, data governance (privacy & security), ethics framework.
- **Resource center.** Good-practice guides (neuro-data, evaluation/robustness, safe-use), documentation templates.

- **Ecosystem voice.** Use cases (BCI, rehab, imaging, triage), sector milestone calendar, neutral partner briefs.

Why it's defensible. **Exact term + .ai** with C-suite readability; **semantic lock** as the ecosystem adopts your wording.

2) Context & milestones

2025–2030: acceleration of **Neuro/AI programs** (sensors, BCI, imaging, digital biomarkers), rising expectations on **data & safety**, and **governance/evaluation** (quality, risk management, traceability).

Implication. Immediate need for a neutral banner to orchestrate **R&D, data, safety/ethics, partnerships** and communication.

3) Three concrete deployments (orders of magnitude)

A. Health/tech enterprise (group program). Neuro/AI governance, portfolio selection, evaluation & risk framework. Impact: **–6 to –10%** project time; **€0.8–2.0M** coordination/communication savings over **12–18 months**.

B. Scale-up / Medtech / BCI vendor. Instant credibility (public reference), shorter cycles, **+€1–3M pipeline** (by ACV/segment).

C. Alliance / Institution (neutral hub). Shared references, data & metric standards, **network effects**.

4) Strategic edge of the pack

Authority through **Neuro/AI** language. C-level clarity. **Defensive** (exact-match .ai, readable, memorable). **Re-use** of content, kits and relationships on a single surface (talent, partners, investors).

5) Market size & pressure

Strong investment momentum in **neurotechnology & digital health** (R&D, data, safety, evaluations). Buyers need a **narrative standard** and a **visible hub**; **NEUROMAX.AI** provides both.

6) CFO anchors (obligatory)

6.1 Alternative cost — awareness & adoption. Without an exact-match: 6–12-month

campaign, internal brand architecture, change management. **Order: €0.4–1.5M / 12–18 months.**

6.2 Cost of delay. Slip one budgeting cycle = rework, delayed partnerships, unselected dossiers. **Order: €0.8–2.0M / 12–18 months** (mid/large).

6.3 Reusable synergies. Under a **single banner**, each euro (content, kits, connectors, relationships) is **re-used** → shorter time-to-trust, faster cycles, lower unit costs.

7) Investment logic (no public pricing)

SEO & memorability (exact term). **Strategic premium** (language control + 2025–2028 window). **Budget lens:** instead of spreading **€0.4–1.5M** across campaigns/change, a **single asset** accelerates partner adoption and reduces trust-acquisition cost.

8) Related assets / bundle option (≤2)

- **neuralaccess.ai** — identity/access/consent (IAM/CIAM) to secure access to neuro-data. *(add-on, not included)*

- **bciaccess.com** — BCI access/consent protocols (interoperability & governance). *(add-on, not included)*

(No other names cited. No claims beyond scope.)

9) Clean acquisition process (Legal/Finance)

Scope of sale: neuromax.ai only.

Escrowed transaction, fast technical transfer, invoice. Options: **cash / staggered 40-30-30 / bundle**. NDA and asset audit available.

Legal notice: descriptive name, **no affiliation; no medical claims.**

10) Contacts

Email • contact@neuromax.ai

Website • <https://www.neuromax.ai>

LinkedIn • <https://www.linkedin.com/company/neuromaxai>